If the focus is purely on weight-loss potential rather than market familiarity, retatrutide has the stronger science-driven case
When this hormone binds to receptors in the brain, pancreas, stomach, and elsewhere, several things happen: Appetite is significantly reduced, with many patients reporting a dramatic decrease in food cravings Gastric emptying slows, meaning food stays in the stomach longer and fullness is sustained after smaller meals Blood sugar regulation improves, reducing the energy spikes and dips that typically drive overeating Interest in high-calorie and highly processed foods often reduces, an effect many patients describe as the food noise quietening Mounjaro (tirzepatide) adds a second mechanism by also activating the GIP receptor
Eight papers did not report any significant correlation with ghrelin or GLP-1, while two papers were excluded from the meta-analysis because they reported follow-up analyses of data that had already been included
In a 12-week clinical trial, participants lost weight and saw a reduction in waist/hips measurements